VPS35 and Parkinson disease: However, several attempts were made to identify a disease-modifying agent in PD by targeting the inflammation, leucine-rich repeat kinase 2 (LRRK2), DJ-1, parkin, PTEN-induced kinase 1 (PINK1), α-synuclein, and vps35 roles in the pathogenesis of PD.